Adrenergic Receptors and Fat Cells: Differential Recruitment by Physiological Amines and Homologous Regulation

The control of fat cell lipolysis by the catecholamines involves at least four different adrenoceptor subtypes; three β (β1-, β2-, and β3-ARs) and one α2-adrenoceptor(α2-AR). The physiological importance of the β- and α2A-ARs varies according to the species, the sex, the age, the anatomical location of fat deposits and the degree of obesity in humans and animals. The physiological amines operate through differential recruitment of these sites on the basis of their relative affinities. This point has been assessed by in vitro studies and has partly been confirmed in in vivo experiments using selected a/β-AR antagonists and in situ microdialysis. The affinity of the β3-AR for catecholamines is less than that of the classical β1- and β2-ARs in the various species investigated. Conversely, it is the α2-AR which exhibit the highest affinity for the physiological amines in all fat cells. The relative order of affinity of the various fat cell ARs for the physiological amines defined in binding studies and in vitro ass ays is α2 > β1 > β2 > β3 for norepinephrine and α2 >β2 > β1> β3 for epinephrine. When considering differential β-AR recruitment by catecholamines, it is the β1-AR which is always activated at the lowest norepinephrine levels, whatever the species, while the activation of the β3-AR requires higher norepinephrine levels. In addition to the differential recruitment, differential regulation by hormones could also occur for each fat cell AR subtype. The α2-and β3-ARs are less prone to desensitization and down-regulation by comparison with the β1- and β2-AR.     

Content of beta-LPH and its fragments (including endorphins) in anterior and intermediate lobes of the bovine pituitary gland

Radioimmunoassays (RIAs) specific for β-LPH_1–47, β-endorphin, α-MSH and β-MSH have been used to identify immunoreactive components in acid extracts from anterior and intermediate lobes of bovine pituitary gland after separation by chromatography on Sephadex G-50. When components in extracts of both lobes, eluting at the same position, were measured with the β-endorphin and β-LPH_1–47 RIA systems, marked quantitative differences were seen. The main components reacting with the β-LPH_1–47 system in anterior pituitary extract co-migrated with β-LPH and γ-LPH while in the intermediate lobe, the main immunoreactive component eluted at a position slightly later than β-endorphin. When the β-endorphin RIA system was used, relatively low amounts of immunoreactive material co-migrating with β-endorphin were seen in the anterior lobe extract while a highly predominant peak eluting at a position slightly later than β-endorphin was observed in intermediate lobe extract. Some β-MSH was seen in the intermediate lobe. These date indicate that the processing of β-LPH is markedly different in the anterior and intermediate bovine pituitary lobes: β-endorphin immunoreactive material predominates in the intermediate lobe whereas β-LPH and γ-LPH predominate in the anterior lobe.     

Distinct requirements for beta-catenin in pancreatic epithelial growth and patterning

Pancreatic exocrine and endocrine lineages arise from multipotent pancreatic progenitor cells (MPCs). Exploiting the mechanisms that govern expansion and differentiation of these cells could enhance efforts to generate β-cells from stem cells. Although our prior work indicates that the canonical Wnt signaling component β-catenin is required qualitatively for exocrine acinar but not endocrine development, precisely how this requirement plays out at the level of MPCs and their lineage-restricted progeny is unknown. In addition, the contribution of β-catenin function to β-cell development remains controversial. To resolve the potential roles of β-catenin in development of MPCs and β-cells, we generated pancreas- and pre-endocrine-specific β-catenin knockout mice. Pancreas-specific loss of β-catenin produced not only a dramatic reduction in acinar cell numbers, but also a significant reduction in β-cell mass. The loss of β-cells is due not to a defect in the differentiation of endocrine precursors, but instead correlates with an early and specific loss of MPCs. In turn, this reflects a novel role for β-catenin in maintaining proximal–distal patterning of the early epithelium, such that distal MPCs resort to a proximal, endocrine-competent “trunk” fate when β-catenin is deleted. Moreover, β-catenin maintains proximal–distal patterning, in part, by inhibiting Notch signaling. Subsequently, β-catenin is required for proliferation of both distal and proximal cells, driving overall organ growth. In distinguishing two distinct roles for β-catenin along the route of β-cell development, we suggest that temporally appropriate positive and negative manipulation of this molecule could enhance expansion and differentiation of stem cell-derived MPCs.     

A novel therapeutic combination of sitagliptin and melatonin regenerates pancreatic β-cells in mouse and human islets

Autoimmune-led challenge resulting in β-cell loss is responsible for the development of type 1 diabetes (T1D). Melatonin, a pineal hormone or sitagliptin, a dipeptidyl peptidase IV (DPP-IV) inhibitor, has increased β-cell mass in various diabetic models and has immunoregulatory property. Both β-cell regenerative capacity and melatonin secretion decrease with ageing. Thus, we aimed to investigate the therapeutic potential of melatonin combined with sitagliptin on β-cell regeneration under glucotoxic stress, in the streptozotocin-induced young and old diabetic mouse models, and euglycemic humanized islet transplant mouse model. Our results suggest that combination therapy of sitagliptin and melatonin show an additive effect in inducing mouse β-cell regeneration under glucotoxic stress, and in the human islet transplant mouse model. Further, in the young diabetic mouse model, the monotherapies induce β-cell transdifferentiation and reduce β-cell apoptosis whereas, in the old diabetic mouse model, melatonin and sitagliptin induce β-cell proliferation and β-cell transdifferentiation, and it also reduces β-cell apoptosis. Further, in both the models, combination therapy reduces fasting blood glucose levels, increases plasma insulin levels and glucose tolerance and promotes β-cell proliferation, β-cell transdifferentiation, and reduces β-cell apoptosis. It can be concluded that combination therapy is superior to monotherapies in ameliorating diabetic manifestations, and it can be used as a future therapy for β-cell regeneration in diabetes patients.     

β-Arrestin 1 and 2 similarly influence μ-opioid receptor mobility and distinctly modulate adenylyl cyclase activity

β-Arrestins are known to play a crucial role in GPCR-mediated transmembrane signaling processes. However, there are still many unanswered questions, especially those concerning the presumed similarities and differences of β-arrestin isoforms. Here, we examined the roles of β-arrestin 1 and β-arrestin 2 at different levels of μ-opioid receptor (MOR)-regulated signaling, including MOR mobility, internalization of MORs, and adenylyl cyclase (AC) activity. For this purpose, naïve HEK293 cells or HEK293 cells stably expressing YFP-tagged MOR were transfected with appropriate siRNAs to block in a specific way the expression of β-arrestin 1 or β-arrestin 2. We did not find any significant differences in the ability of β-arrestin isoforms to influence the lateral mobility of MORs in the plasma membrane. Using FRAP and line-scan FCS, we observed that knockdown of both β-arrestins similarly increased MOR lateral mobility and diminished the ability of DAMGO and endomorphin-2, respectively, to enhance and slow down receptor diffusion kinetics. However, β-arrestin 1 and β-arrestin 2 diversely affected the process of agonist-induced MOR endocytosis and exhibited distinct modulatory effects on AC function. Knockdown of β-arrestin 1, in contrast to β-arrestin 2, more effectively suppressed forskolin-stimulated AC activity and prevented the ability of activated-MORs to inhibit the enzyme activity. Moreover, we have demonstrated for the first time that β-arrestin 1, and partially β-arrestin 2, may somehow interact with AC and that this interaction is strongly supported by the enzyme activation. These data provide new insights into the functioning of β-arrestin isoforms and their distinct roles in GPCR-mediated signaling.     

Acetylated and nonacetylated forms of beta-endorphin in rat brain and pituitary

Extracts of rat posterior intermediate pituitary and extracts of brains from normal and hypophysectomized rats were separated by gel filtration chromatography and fractions were analyzed by both a classical β-endorphin radioimmunoassay and by a radioimmunoassay specific for α-N-acetyl β-endorphin. In posterior intermediate pituitary extracts, more than 90 percent of the β-endorphin-sized immunoreactive material was α-N-acetylated. In extracts of brains from normal rats, less than 2 percent of the β-endorphin-sized immunoreactive material corresponded to α-N-acetylβ-endorphin, whereas in brains from hypophysectomized animals, no α-N-acetylβ-endorphin-like material could be detected. Immunofluorescence on normal brain sections, using either affinity purified antibodies to α-N-acetylβ-endorphin or conventional β-endorphin antibodies, showed no α-N-acetylβ-endorphin immunoreactivity in β-endorphin neurons. Only in brain sections which had been acetylated $\text{in}\text{vitro}$ prior to immunostaining could α-N-acetylβ-endorphin-like material be detected in the β-endorphin neurons. These results suggest that—in contrast to the cells in the intermediate lobe of the pituitary—the β-endorphin in brain neurons is not α-N-acetylated and that the small amount of α-N-acetyl β-endorphin which can be found in extracts of brains from normal animals is probably of pituitary origin.     

Biosynthesis of beta-endorphin, beta-lipotropin and the putative ACTH-LPH precursor in the frog pars intermedia.

When frog pars intermedia are incubated for 3 h with radioactive methionine, the predominant labeled peptide is one with an apparent molecular weight of 33, 100. This peptide can be immunoprecipitated with antisera against β-melanotropin (β-MSH), adrenocorticotrophin (ACTH), and β-endorphin and is believed to be the common precursor of ACTH and β-lipotropin (β-LPH). Immunoprecipitation experiments have also demonstrated the presence of labeled β-LPH and β-endorphin. The labeled β-endorphin has been shown to behave identically to sheep β-endorphin on both carboxymethyl-cellulose chromatography and polyacrylamide gel electrophoresis. Frog β-endorphin has methionine as the fifth residue, as do all other β-endorphins that have been sequenced.     

Free and Protein-bound β-Amylases of Barley Grain. Characterization by Two-dimensional Immunoelectrophoresis

The β-amylases of ungerminated barley (Hordeum distichum L. cv. Emir) were characterized by two-dimensional immunoelectrophoretic techniques in order to elucidate the structure and physiological importance of the latent β-amylase present in cereal grains. Two water-soluble forms with partial immunochemical identity were detected. One of the enzyme forms was found to consist of aggregates between β-amylase and an immunochemically distinct non-active protein. Both β-amylase and the protein could be released from the aggregates with β-mercaptoethanol and, to some extent, with papain. β-Mercaptoethanol increased the extractability of β-amylase and of the non-active protein. The aggregated form of β-amylase was found to predominate in extracts made in the presence of papain. Possible functions of the non-enzymatic protein in formation of latent β-amylase is discussed.     

Beta-D-galactosidase and beta-D-fucosidase of pig kidney

Four forms of β-d-galactosidase were separated by gel filtration on Sephadex G-200. Lactose was hydrolysed by three of the forms but not by the fourth form which also exhibited β-d-fucosidase activity. The elution profiles of β-d-galactosidase and β-d-fucosidase in the fourth form were similar. A comparison of the properties of β-galactosidase and β-d-fucosidase showed that both activities had similar pH optima, pH stability, and thermostability and were inhibited to the same extent by inhibitors. These data suggest that the same enzyme catalyses the hydrolysis of both substrates.     

Autoantibodies and monoclonal antibodies in the purification and molecular characterization of neurotransmitter receptors

The combination of immunological advances with membrane receptor research has promoted rapid progress in the molecular characterization of neurotransmitter receptor molecules. We have to date produced monoclonal antibodies to β₁-, β₂-, and β₁-adrenergic, D₂-dopaminergic, and muscarinic receptors. In addition we have discovered that some allergic respiratory disease patients possess circulating autoantibodies to β₂-adrenergic receptors. These antireceptor antibodies in conjunction with specific receptor affinity reagents have allowed us to isolate, purify, and begin to characterize α- and β-adrenergic, dopaminergic, and muscarinic receptors. For example, immunoprecipitation of turkey erythrocyte β₁ receptors with monoclonal antibodies yields a single polypeptide M_r 65–70 K. In contrast, purification of β₂-adrenergic receptors using either autoantibodies or monoclonal antibodies yields a receptor species with a subunit of M_r 55–59 K. Autoantibodies to β₂ receptors demonstrate a 50–100% homology among β₂ receptors from humans to rats, whereas monoclonal antibody FV-104 recognizes a determinant in the ligand binding site of all β₁ and β₂ receptors tested to date. These data suggest that β₁- and β₂-adrenergic receptors may have evolved from a common ancestor, perhaps by gene duplication.     

Agonist-directed interactions with specific beta-arrestins determine mu-opioid receptor trafficking, ubiquitination, and dephosphorylation

Morphine and other opiates mediate their effects through activation of the μ-opioid receptor (MOR), and regulation of the MOR has been shown to critically affect receptor responsiveness. Activation of the MOR results in receptor phosphorylation, β-arrestin recruitment, and internalization. This classical regulatory process can differ, depending on the ligand occupying the receptor. There are two forms of β-arrestin, β-arrestin1 and β-arrestin2 (also known as arrestin2 and arrestin3, respectively); however, most studies have focused on the consequences of recruiting β-arrestin2 specifically. In this study, we examine the different contributions of β-arrestin1- and β-arrestin2-mediated regulation of the MOR by comparing MOR agonists in cells that lack expression of individual or both β-arrestins. Here we show that morphine only recruits β-arrestin2, whereas the MOR-selective enkephalin [D-Ala(2),N-Me-Phe(4),Gly(5)-ol]enkephalin (DAMGO), recruits either β-arrestin. We show that β-arrestins are required for receptor internalization and that only β-arrestin2 can rescue morphine-induced MOR internalization, whereas either β-arrestin can rescue DAMGO-induced MOR internalization. DAMGO activation of the receptor promotes MOR ubiquitination over time. Interestingly, β-arrestin1 proves to be critical for MOR ubiquitination as modification does not occur in the absence of β-arrestin1 nor when morphine occupies the receptor. Moreover, the selective interactions between the MOR and β-arrestin1 facilitate receptor dephosphorylation, which may play a role in the resensitization of the MOR and thereby contribute to overall development of opioid tolerance.     

Presence of immunoreactive β-lipotropin and β-endorphin in human placenta

Utilizing a sensitive radioimmunoassay capable of detecting both β-lipotropin (β-LPH) and β-endorphin (β-EP), we demonstrated the existence of immunoreactive β-LPH and β-EP in extracts of human placentas. Gel chromatographic studies revealed that total β-EP immunoreactivity consists of two fractions with elution positions compatible with β-LPH and β-EP, respectively, and a fraction of larger molecular weight. All three fractions showed parallel curves with the standard curve of β-EP in radioimmunoassay. Our observations suggests that β-EP, β-LPH and possibly their precursor exist in human placenta.     

Apparent structural differences at the tetramerization region of erythroid and nonerythroid beta spectrin as discriminated by phage displayed scFvs

We have screened a human immunoglobulin single-chain variable fragment (scFv) phage library against the C-terminal tetramerization regions of erythroid and nonerythroid beta spectrin (βI-C1 and βII-C1, respectively) to explore the structural uniqueness of erythroid and nonerythroid β-spectrin isoforms. We have identified interacting scFvs, with clones "G5" and "A2" binding only to βI-C1, and clone "F11" binding only to βII-C1. The K(d) values, estimated by competitive enzyme-linked immunosorbent assay, of these scFvs with their target spectrin proteins were 0.1-0.3 μM. A more quantitative K(d) value from isothermal titration calorimetry experiments with the recombinant G5 and βI-C1 was 0.15 μM. The α-spectrin fragments (model proteins), αI-N1 and αII-N1, competed with the βI-C1, or βII-C1, binding scFvs, with inhibitory concentration (IC(50) ) values of ～50 μM for αI-N1, and ～0.5 μM for αII-N1. Our predicted structures of βI-C1 and βII-C1 suggest that the Helix B' of the C-terminal partial domain of βI differs from that of βII. Consequently, an unstructured region downstream of Helix B' in βI may interact specifically with the unstructured, complementarity determining region H1 of G5 or A2 scFv. The corresponding region in βII was helical, and βII did not bind G5 scFv. Our results suggest that it is possible for cellular proteins to differentially associate with the C-termini of different β-spectrin isoforms to regulate α- and β-spectrin association to form functional spectrin tetramers, and may sort β-spectrin isoforms to their specific cellular localizations.     

Measurement of beta-guanidinopropionate and phosphorylated beta-guanidinopropionate in tissues.

The Sakaguchi color reaction for monosubstituted guanidino compounds was applied to the measurement of β-guanidinopropionate and phosphorylated β-guanidinopropionate. The phosphorylated derivative was measured as an increase in β-guanidinopropionate following incubation with 0.1n HCl in a boiling-water bath for 10 min. After feeding rats 1% of β-guanidinopropionic acid in their diet for 69 days, skeletal muscle, heart, liver, kidney, and spleen contained 5–10 μmoles of a monosubstituted guanidino compound per gram wet weight of tissue. No β-guanidinopropionate was detected in brain or testes. Phosphorylated β-guanidinopropionate was found only in skeletal muscle (27 μmoles/g) and in heart (7 μmoles/g). Creatine hydrate (2%) added to the diet containing β-guanidinopropionic acid inhibited the accumulation of phosphorylated β-guanidinopropionate in the heart and partially inhibited its accumulation in skeletal muscle.     

Beta carotene and its oxidation products have different effects on microsome mediated binding of benzo[a]pyrene to DNA

The effects of β-carotene (βC) and its oxidation products on the binding of benzo[a]pyrene (BaP) metabolites to calf thymus DNA was investigated in the presence of rat liver microsomes. Mixtures of βC oxidation products (βCOP) as well as separated, individual βC oxidation products were studied. One set of experiments, for example, involved the use of the mixture of βCOP obtained after a 2-h radical-initiated oxidation. For this data set, the incorporation of unoxidized βC into microsomal membranes caused the level of binding of BaP metabolites to DNA to decrease by 29% over that observed in the absence of βC; however, the incorporation of the mixture of βCOP caused the binding of BaP metabolites to DNA to increase 1.7-fold relative to controls without βC. Two variations of this experiment were studied: (1) When no NADPH was added, βC decreased the binding of BaP metabolites to DNA by 19%, but the mixture of βCOP increased binding by 3.3-fold relative to that observed in the absence of βC. (2) When NADPH was added under near-anaerobic conditions, βC caused an almost total (94%) decrease in binding whereas βCOP had no effect on the amount of binding relative to that observed in the absence of βC. Both βCOP and cumene hydroperoxide caused BaP metabolites to bind to DNA even when NADPH was omitted from the incubation mixture. Separation of the mixture of βC oxidation products into fractions by HPLC allowed preliminary testing of individual βC oxidation products separately; of the various fractions tested, the products tentatively identified as 11,15′-cyclo-12,15-epoxy-11,12,15,15′-tetrahydro-β-carotene and β-carotene-5,6-epoxide appeared to cause the largest increase in BaP-DNA binding. Microsomes from rats induced with 3-methylcholanthrene (3MC) or Aroclor 1254 produced different levels of binding in some experimental conditions. We hypothesize that, under some conditions, the incorporation of βC into microsomal membranes can be protective against P450-catalyzed BaP binding to DNA; however, the incorporation of βCOP facilitates the formation of BaP metabolites that bind DNA, although only certain P450 isoforms catalyze the binding process.     

beta-Endorphin in human plasma: basal and pathologically elevated levels.

β-Endorphin-like immunoreactivity was measured in plasma of normal human subjects and in plasma of patients with pathologically elevated ACTH levels. The antiserum used displayed the same avidity for human β-endorphin and human β-lipotropin (detection limit for both peptides 1–2 fmoles/tube). Gel chromatography of the immunoreactive components in plasma of normal subjects indicated the presence of both β-lipotropin (2.1 -10.1 fmoles/ml) and β-endorphin (3.5–6.4 fmoles/ml). A close correlation between immunoreactive β-endorphin and ACTH was found in plasma of patients suffering from Addison's disease, Cushing's disease and exhibiting Nelson's syndrome. Elevated levels of β-endorphin-like immunoreactivity in plasma of these patients were due to both β-lipotropin and β-endorphin.     

Evidence for a single catalytic and two binding sites in the almond emulsin β-D-glucosidase molecule

An isoenzyme of glucosidase- isolated from sweet almond emulsin - and composed of a β-D-glucosidase, a β-D-galactosidase and a β-D-fucosidase, has been shown to possess β-D-xylosidase activity, as well. On the basis of the following results it has been concluded that the β-D-glucosidase and β-D-galactosidase activities reside in one catalytic site, but there are two kinetically distinst binding sites in the active center: 1./D-Glucono-1,5-lactone is shown to excert competitive inhibition on the hydrolysis of β-D-glucopyranoside and non-competitive inhibition on the hydrolysis of β-D-galactopyranoside. 2./ D-galactono-1,5-lactone competitively inhibits the hydrolysis of β-D-galactopyranoside, but possesses non-competitive inhibition on the hydrolysis of β-D-glucopyranoside. 3./ When the enzyme is incubated with two p-nitrophenyl glycoside substrates at or above their respective K_m values, the rate of p-nitrophenol formation is not additive but rather it is equal to the value calculated from the individual K_m values and relative maximum rates.     

Sialidase Treatment Exposes the βT1-Integrin Active Ligand Binding Site on HL60 Cells and Increases Binding to Fibronectin

The migration of neutrophils from the circulation to areas of inflammation is the result of the sequential activation of multiple cellular adhesion molecules. βT1-Integrins are cell surface glycoproteins and the class of adhesion molecules responsible for binding to the extracellular matrix. The goal of this study was to determine the contribution of glycosylation, specifically the presence of sialic acid, to βT1-integrin adhesion in a neutrophil model. βT1-Integrins on differentiated HL60 cells were remodeled by treatment with the exoglycosidases, sialidase and βT-galactosidase. βT1-Integrin activity was determined by measuring adherence to the extracellular matrix protein fibronectin. The expression of βT1-integrins, βT2-integrins and activated βT1-integrins was determined by flow cytometry. Remodeling of βT1-integrins by treatment with sialidase increased adhesion by greater than 100%. Flow cytometric analysis of remodeled βT1-integrins demonstrated an increased expression of the activated βT1-integrin, but only minor increases in the expression of total βT1-and βT2-integrins. We postulate that glycosidase treatment increases adhesion and expression of activated βT1-integrins by exposure of the normally hidden ligand-binding site. The glycosylation of βT1-integrins on neutrophils may act to hide the ligand-binding site in unstimulated cells thereby contributing to the affinity modulation observed in neutrophil pl-integrin function.